Conjugated Estrogen is indicated in–

• Moderate-to-severe vasomotor symptoms associated with estrogen deficiency
• Prevention and management of osteoporosis related to estrogen deficiency
• Reduction of the risk of coronary heart disease and related mortality in postmenopausal women
• Atrophic vaginitis and atrophic urethritis
• Female hypoestrogenism

Vasomotor symptoms associated with estrogen deficiency: Hot flushes, characterized by sudden feelings of heat over the upper body and face along with sweating, are experienced by many postmenopausal women due to declining ovarian hormone levels. These symptoms may also occur after surgical menopause. Clinical studies have shown that Conjugated Estrogen significantly reduces the frequency and severity of hot flushes in menopausal women.

Osteoporosis associated with estrogen deficiency: Estrogen replacement therapy is considered an effective option for preventing osteoporosis in postmenopausal women. Estrogen helps reduce bone loss and lowers the risk of hip and wrist fractures. Studies indicate that even when therapy is initiated several years after menopause, it may still help preserve bone mass, although the benefits continue only while treatment is maintained.

Cardiovascular benefit: Various clinical and observational studies have explored the relationship between estrogen therapy and cardiovascular disease in postmenopausal women. Findings suggest that estrogen replacement therapy may help reduce the risk of coronary heart disease, partly through beneficial effects on lipid profiles and lipoproteins. However, additional lifestyle measures such as exercise, dietary modification, and smoking cessation remain important for cardiovascular protection.

Atrophic vaginitis and atrophic urethritis associated with estrogen deficiency: Lack of estrogen may cause thinning and dryness of vaginal and urethral tissues, leading to itching, discomfort, painful intercourse, and urinary symptoms. Estrogen replacement therapy can reverse many of these changes and improve symptoms.

Female hypoestrogenism: Estrogen replacement therapy is also indicated in conditions of female hypoestrogenism caused by ovarian failure, hypogonadism, or other causes of estrogen deficiency. Treatment may help maintain normal female characteristics and reduce osteoporosis risk.

Conjugated estrogens for oral use are a mixture of estrogens derived from natural sources, mainly from pregnant mares’ urine. These preparations contain water-soluble sulfate esters of estrone, equilin, and related estrogenic compounds.

Estrogens play a crucial role in the development and maintenance of the female reproductive system and secondary sexual characteristics. They support the growth of the uterus, vagina, fallopian tubes, and breasts, and contribute to bone health, skin tone, and the distribution of body hair. Estrogens also influence the release of pituitary gonadotropins and regulate various reproductive functions.

The pharmacological effects of conjugated estrogens are similar to naturally occurring endogenous estrogens. In responsive tissues, estrogens enter cells and bind to nuclear receptors, leading to specific RNA and protein synthesis. Oral administration of conjugated estrogens can increase HDL cholesterol and reduce LDL cholesterol levels, contributing to improved lipid profiles and potential cardiovascular benefits in postmenopausal women.

Conjugated estrogens are readily absorbed from the gastrointestinal tract. They are mainly metabolized in the liver and may undergo enterohepatic circulation before being excreted through the kidneys.

Osteoporosis: 0.625 mg daily. This dose is required for bone mass conservation.

Cardiovascular benefit: 0.625 mg–1.25 mg daily.

Female hypoestrogenism: 0.3 mg–1.25 mg daily. Doses are adjusted depending on the severity of symptoms and responsiveness of the endometrium. Dose should be individualized to achieve optimum patient response.

Administration of Conjugated Estrogen may be continuous (e.g. without a break in therapy) or cyclic (e.g. three weeks on and one week off.) The lowest effective dose should be administered. Conjugated Estrogen can be used concomitantly with progestogen.

The addition of a progestogen during estrogen administration reduces the risk of endometrial hyperplasia and endometrial carcinoma, which have been associated with the use of unoposed estrogen. Morphological and biochemical studies of the endometrium suggest that an adequate dose of progestogen for at least 10-14 days per cycle will significantly reduce hyperplastic changes. Since progestogens are administered to reduce the risk of hyperplastic hanges of the endometrium, patients without a uterus do not require a progestogen for this purpose.

Numerous reports of ingestion of large doses of estrogen-containing oral contraceptives by young children indicate that acute serious ill effects have not been observed. Overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females.

Rifampin may reduce the estrogenic effect when used together with estrogen therapy. This interaction is believed to occur due to increased metabolism of estrogen through induction of hepatic microsomal enzymes.

• Known or suspected breast cancer
• Known or suspected estrogen-dependent tumors
• Known or suspected pregnancy
• Undiagnosed abnormal genital bleeding
• Active thrombophlebitis or thromboembolic disorders
• Hypersensitivity to any component of Conjugated Estrogen tablets

Serious adverse reactions related to estrogen therapy are described under Warnings and Precautions. Additional reported side effects include:

• Genitourinary system: Breakthrough bleeding, spotting, menstrual irregularities, amenorrhea
• Breasts: Breast tenderness, enlargement, discharge
• Gastrointestinal: Nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice
• Skin: Chloasma or melasma that may persist after discontinuation, alopecia, rash
• Eyes: Increased corneal curvature, intolerance to contact lenses
• Central nervous system: Headache, migraine, dizziness, chorea
• Miscellaneous: Weight gain or loss, edema, changes in libido, worsening of porphyria

As a general guideline, medications should be used during breastfeeding only when clearly necessary, since many drugs may pass into human breast milk.

A complete medical and family history should be evaluated before starting estrogen therapy. Physical examinations, including blood pressure measurement, breast, abdominal, pelvic examination, and Pap smear, should be performed before and during treatment. Women with an intact uterus should be monitored regularly for signs of endometrial hyperplasia or cancer, especially if using concurrent progestogen therapy.

Any abnormal vaginal bleeding should be investigated promptly to rule out malignancy. Estrogen therapy may increase the size of uterine fibroids in some women. There may also be an increased risk of thrombophlebitis and thromboembolic disorders, although evidence is not conclusive. Estrogens are not proven effective for treating nervous symptoms or depression associated with menopause.

If possible, estrogen therapy should be stopped at least four weeks before surgery associated with a high risk of thromboembolism or during prolonged immobilization. Conditions such as asthma, epilepsy, migraine, heart disease, or kidney dysfunction may worsen due to fluid retention caused by estrogens and require close observation.

Patients with impaired liver function may metabolize estrogen poorly and should use it cautiously. Estrogen therapy should also be used carefully in patients with metabolic bone diseases associated with hypercalcemia. Women should be informed that menstrual bleeding may return during therapy and that Conjugated Estrogens are not contraceptives. Non-hormonal contraceptive methods are advised for women of childbearing potential.

Symptoms of estrogen overdose in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding in females. There is no specific antidote; treatment should be symptomatic and supportive.

Female Sex hormones

Store in a cool and dry place, protected from light and moisture, at a temperature below 25°C.